<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29267607</article-id><article-id pub-id-type="pmc">5731322</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0154</article-id><article-id pub-id-type="other">4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>B-Type Natriuretic Peptide as a Predictor of Short-Term Mortality in
On-Pump Coronary Artery Bypass Grafting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Murad Junior</surname><given-names>Jamil Alli</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Machado</surname><given-names>Maur&#x000ed;cio Nassau</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fernandes</surname><given-names>Marcio Pimentel</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Soares</surname><given-names>Marcelo Jos&#x000e9; Ferreira</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grigolo</surname><given-names>Ingrid Helen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Singulane</surname><given-names>Cristiane Carvalho</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Godoy</surname><given-names>Moacir Fernandes</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">
<label>1</label> Faculdade de Medicina de S&#x000e3;o Jos&#x000e9; do Rio Preto
(FAMERP), S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Jamil Alli Murad Junior, Faculdade de
Medicina de S&#x000e3;o Jos&#x000e9; do Rio Preto, Av. Brigadeiro Faria Lima, 5416
- S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil. Zip code: 15090-000. E-mail:
<email>jmuradjr@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2017</year></pub-date><volume>32</volume><issue>6</issue><fpage>462</fpage><lpage>467</lpage><history><date date-type="received"><day>23</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The present study refers to a determination of the preoperative B-type
natriuretic peptide is a predictor of short-term all-cause mortality in
patients undergoing on-pump coronary artery bypass graft surgeries.</p></sec><sec><title>Methods</title><p>Two hundred and twenty-one patients undergoing on-pump coronary artery bypass
graft surgeries were evaluated prospectively during a 30-day postoperative
follow-up period. Serum B-type natriuretic peptide concentration was
measured without a 24-hour period prior to the surgical procedure and the
value obtained was correlated with a short-term all-cause mortality.</p></sec><sec><title>Results</title><p>Data analysis showed that all-cause mortality rates were equal to 9.5% in 30
days. Accuracy analysis by the receiver operating characteristic curve found
an ideal cut-off value of B-type natriuretic peptide equal to 150 pg/mL in
relation to mortality (AUC=0.82, 95% CI=0.71-0.87,
<italic>P</italic>&#x0003c;0.001). Multivariate analysis showed that B-type
natriuretic peptide value greater than or equal to 150 pg/mL
(<italic>P</italic>=0.030, HR=3.99, 95% CI=1.14-13.98) was an
independent predictor of all-cause mortality in a 30-day follow-up
period.</p></sec><sec><title>Conclusion</title><p>Preoperative serum B-type natriuretic peptide concentration is an independent
predictor of short-term all-cause mortality in patients undergoing coronary
artery bypass grafting with cardiopulmonary bypass.</p></sec></abstract><kwd-group><kwd>Natriuretic Peptides</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Prospective Studies</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BNP</td><td align="left" rowspan="1" colspan="1">= B-type natriuretic peptide</td></tr><tr><td align="left" rowspan="1" colspan="1">CABG</td><td align="left" rowspan="1" colspan="1">= Coronary artery bypass grafting</td></tr><tr><td align="left" rowspan="1" colspan="1">HR</td><td align="left" rowspan="1" colspan="1">= Hazard ratio</td></tr><tr><td align="left" rowspan="1" colspan="1">OPCABG</td><td align="left" rowspan="1" colspan="1">= On-pump coronary artery bypass grafting</td></tr><tr><td align="left" rowspan="1" colspan="1">ROC</td><td align="left" rowspan="1" colspan="1">= Receiver operating characteristic</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Since its introduction in the 1960s, coronary artery bypass grafting (CABG) is the
most studied surgical procedure in medical history and rapidly as the standard
treatment for patients with extensive coronary artery disease<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>In the last decades, there has been a significant decline in short-term mortality for
this procedure. This work can be attributed to an improvement in the surgical
technique combined with the significant progress in perioperative care, as well as
the development and diffusion of databases that provide a better definition and
understanding of variables that impact on mortality after CABG<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>This stabilization of mortality is a challenge for the discovery of new variables to
predict mortality in order to further improve the care related to this procedure. In
this context, due to its close correlation with ventricular parietal stress and
clinical and hemodynamic variables that determine a higher cardiovascular risk,
B-type natriuretic peptide (BNP) has been investigated as a new prognostic tool to
predict mortality in cardiac surgery<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>In this study, the objective is to evaluate whether the preoperative BNP
concentration is an independent predictor of short-term all-cause mortality in
patients undergoing on-pump coronary artery bypass grafting (OPCABG).</p></sec><sec sec-type="methods"><title>METHODS</title><p>Patients consecutively submitted to OPCABG admitted to the Intensive Care Unit in the
postoperative period of cardiac surgeries at Hospital de Base of S&#x000e3;o
Jos&#x000e9; do Rio Preto (SP, Brazil). Patients younger than 18 years of age,
advanced neoplasia or those who underwent a combined cardiac procedure, congenital
surgery, cardiac transplantation, aortic surgery, valve surgery and off-pump
coronary artery bypass surgery were excluded.</p><p>The OPCABG were performed by median transsternal thoracotomy with extracorporeal
circulation, aorta-bicaval cannulation, transverse aortic clamping and antegrade and
retrograde cardioplegia using normothermic blood solution. Patients were treated
according to European and American guidelines in force at the time<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>The data were prospectively collected through a computerized database of the Hospital
de Base of S&#x000e3;o Jos&#x000e9; do Rio Preto for an average follow-up period of 30
days. The study protocol was approved by the local ethics committee (CAAE
53306916.8.0000.5415).</p><p>Variables included in the study were demographic, preoperative comorbidities, degree
of left ventricular systolic dysfunction, intraoperative variables, and all-cause
mortality in 30 days. The definition of all variables, as well as the indication and
performance of the surgical procedures are based on the guidelines published by the
European Society of Cardiology and European Association for Cardio-Thoracic
Surgery<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>The serum concentration of BNP was measured in the immediate preoperative period (24
hours before surgery) in all surgeries by the electrochemiluminescence method using
the Siemens ADVIA Centaur equipment (Siemens Medical).</p><sec><title>Statistical Analysis</title><p>Categorical variables were presented in absolute numbers (percentages) and the
continuous variables in mean and standard deviation or median and interquartile
ranges (Q3-Q1), according to the type of distribution.</p><p>Statistical analysis was performed with SPSS software (version 20.0). The power
to discriminate the preoperative serum concentration of BNP to predict all-cause
mortality within 30 days after surgery was determined by calculating the area
under the Receiver Operating Characteristic (ROC) curve, value &#x0003e; 0.60
considered as not determined by chance.</p><p>In this study, the risk analysis with the Cox proportional regression model was
used to establish the relationship between the dependent variable (all-cause
mortality in 30 days) and the exploratory variables. Univariate variables
related to mortality (<italic>P</italic>&#x02264;0.05) were considered for
multivariate regression analysis. Independent predictors of mortality were
established for the variables with <italic>P</italic>&#x02264;0.05 in the
multivariate analysis.</p><p>The probability of survival during the 30-day follow-up period was estimated by
the Kaplan-Meier method. The log rank test was used to compare the probability
of survival.</p><p>Values with <italic>P</italic>&#x02264;0.05 were considered statistically
significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>In the period evaluated, a total of 730 patients were consecutively submitted to open
cardiac surgical procedures. Two hundred twenty-one patients underwent OPCABG were
included in the study with a 30-day follow-up period in all patients. A total of 509
patients who underwent combined cardiac procedures (71 patients), congenital surgery
(33 patients), cardiac transplantation (17 patients), aortic surgery (25 patients),
valve surgery (313 patients) and off pump CABG (50 patients) (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flowchart for study enrollment and patient outcome (CABG - Coronary
Artery Bypass Graft Surgery, BNP - B -type natriuretic peptide, PO -
postoperative).</p></caption><graphic xlink:href="rbccv-32-06-0462-g01"/></fig>
</p><p>The baseline characteristics of patients undergoing OPCABG evaluated in this study
are summarized in <xref ref-type="table" rid="t1">Table 1</xref>. The median age was
60 (52-67) years and 66% were men. Among the 221 patients, 70 (32%) were diabetic,
192 (87%) had systemic arterial hypertension. Eighty-two (37%) patients had urgency
or emergency surgery, 74 (33%) patients were operated in the presence of acute
coronary syndrome, 43 (19%) patients had moderate or significant left ventricular
dysfunction. Intra-aortic balloon pump was implanted in the preoperative period in
13% of the patients and the mean duration of cardiopulmonary bypass was 94
minutes.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of patients undergoing myocardial revascularization
surgery (N=221), overall and stratified according to the cutoff value of BNP
(150 pg/ml).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Baseline characteristics</th><th align="center" rowspan="1" colspan="1">All patients (221)</th><th align="center" rowspan="1" colspan="1">BNP &#x0003c; 150 pg/mL (111)</th><th align="center" rowspan="1" colspan="1">BNP &#x02265; 150 pg/mL (110)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="3" rowspan="1">Median (25<sup>th</sup> -
75<sup>th</sup>) or N (%)</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">60 (52 - 67)</td><td align="center" rowspan="1" colspan="1">58 (51 - 66)</td><td align="center" rowspan="1" colspan="1">62 (56 - 69)</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Male gender</td><td align="center" rowspan="1" colspan="1">146 (66)</td><td align="center" rowspan="1" colspan="1">75 (68)</td><td align="center" rowspan="1" colspan="1">71 (65)</td><td align="center" rowspan="1" colspan="1">0.635</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">72 (65 - 83)</td><td align="center" rowspan="1" colspan="1">75 (67 - 85)</td><td align="center" rowspan="1" colspan="1">70 (63 - 80)</td><td align="center" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (m)</td><td align="center" rowspan="1" colspan="1">1,66 (1.60 - 1.70)</td><td align="center" rowspan="1" colspan="1">1.66 (1.60 - 1.70)</td><td align="center" rowspan="1" colspan="1">1.65 (1.60 - 1.70)</td><td align="center" rowspan="1" colspan="1">0.772</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27 (24 - 30)</td><td align="center" rowspan="1" colspan="1">28 (25 - 31)</td><td align="center" rowspan="1" colspan="1">26 (24 - 29)</td><td align="center" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU Length of Stay</td><td align="center" rowspan="1" colspan="1">3 (2 - 5)</td><td align="center" rowspan="1" colspan="1">3 (2 - 5)</td><td align="center" rowspan="1" colspan="1">3 (2 - 6)</td><td align="center" rowspan="1" colspan="1">0.342</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute Coronary Syndrome</td><td align="center" rowspan="1" colspan="1">74 (33)</td><td align="center" rowspan="1" colspan="1">22 (20)</td><td align="center" rowspan="1" colspan="1">52 (47)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unstable Angina</td><td align="center" rowspan="1" colspan="1">37 (50)</td><td align="center" rowspan="1" colspan="1">16 (73)</td><td align="center" rowspan="1" colspan="1">21 (40)</td><td align="center" rowspan="3" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Non-ST Elevation MI</td><td align="center" rowspan="1" colspan="1">22 (30)</td><td align="center" rowspan="1" colspan="1">4 (18)</td><td align="center" rowspan="1" colspan="1">18 (35)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ST Elevation MI</td><td align="center" rowspan="1" colspan="1">15 (20)</td><td align="center" rowspan="1" colspan="1">2 (9,0)</td><td align="center" rowspan="1" colspan="1">13 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">LMCA &#x0003e; 50%</td><td align="center" rowspan="1" colspan="1">59 (27)</td><td align="center" rowspan="1" colspan="1">29 (26)</td><td align="center" rowspan="1" colspan="1">30 (27)</td><td align="center" rowspan="1" colspan="1">0.912</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of grafts</td><td align="center" rowspan="1" colspan="1">3 (2 - 3)</td><td align="center" rowspan="1" colspan="1">3 (2 - 3)</td><td align="center" rowspan="1" colspan="1">3 (2 - 3)</td><td align="center" rowspan="1" colspan="1">0.197</td></tr><tr><td align="left" rowspan="1" colspan="1">Urgency/Emergency</td><td align="center" rowspan="1" colspan="1">82 (37)</td><td align="center" rowspan="1" colspan="1">23 (21)</td><td align="center" rowspan="1" colspan="1">59 (54)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD</td><td align="center" rowspan="1" colspan="1">7 (3.2)</td><td align="center" rowspan="1" colspan="1">3 (2,7)</td><td align="center" rowspan="1" colspan="1">4 (3,6)</td><td align="center" rowspan="1" colspan="1">0.722</td></tr><tr><td align="left" rowspan="1" colspan="1">High blood pressure</td><td align="center" rowspan="1" colspan="1">192 (87)</td><td align="center" rowspan="1" colspan="1">93 (84)</td><td align="center" rowspan="1" colspan="1">99 (90)</td><td align="center" rowspan="1" colspan="1">0.171</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">70 (32)</td><td align="center" rowspan="1" colspan="1">26 (23)</td><td align="center" rowspan="1" colspan="1">44 (40)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline SCr (mg/dL)</td><td align="center" rowspan="1" colspan="1">1,10 (0,90 &#x02013; 1.30)</td><td align="center" rowspan="1" colspan="1">1,10 (1,00 &#x02013; 1.30)</td><td align="center" rowspan="1" colspan="1">1.10 (0.90 &#x02013; 1.40)</td><td align="center" rowspan="1" colspan="1">0.761</td></tr><tr><td align="left" rowspan="1" colspan="1">LV dysfunction</td><td align="center" rowspan="1" colspan="1">43 (19)</td><td align="center" rowspan="1" colspan="1">11 (9,9)</td><td align="center" rowspan="1" colspan="1">32 (29)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB time (min)</td><td align="center" rowspan="1" colspan="1">94 (77 - 111)</td><td align="center" rowspan="1" colspan="1">94 (78 - 110)</td><td align="center" rowspan="1" colspan="1">93 (77 - 113)</td><td align="center" rowspan="1" colspan="1">0.763</td></tr><tr><td align="left" rowspan="1" colspan="1">IABP</td><td align="center" rowspan="1" colspan="1">29 (13)</td><td align="center" rowspan="1" colspan="1">9 (8,1)</td><td align="center" rowspan="1" colspan="1">20 (18)</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">Additive EuroSCORE</td><td align="center" rowspan="1" colspan="1">2 (1 - 4)</td><td align="center" rowspan="1" colspan="1">2 (0 - 3)</td><td align="center" rowspan="1" colspan="1">3 (1 - 5)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Low (0 - 2)</td><td align="center" rowspan="1" colspan="1">115 (52)</td><td align="center" rowspan="1" colspan="1">72 (65)</td><td align="center" rowspan="1" colspan="1">43 (39)</td><td align="center" rowspan="4" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Intermediate (3 - 5)</td><td align="center" rowspan="1" colspan="1">73 (33)</td><td align="center" rowspan="1" colspan="1">33 (30)</td><td align="center" rowspan="1" colspan="1">40 (36)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;High (6 - 8)</td><td align="center" rowspan="1" colspan="1">21 (9.5)</td><td align="center" rowspan="1" colspan="1">4 (3.6)</td><td align="center" rowspan="1" colspan="1">17 (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Very high (&#x0003e;9)</td><td align="center" rowspan="1" colspan="1">12 (5.4)</td><td align="center" rowspan="1" colspan="1">2 (1.8)</td><td align="center" rowspan="1" colspan="1">10 (9.0)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BNP = B-type natriuretic peptide; COPD=chronic obstructive pulmonary
disease; CPB=cardiopulmonary bypass; IABP=intra-aortic balloon pump;
ICU=intensive care unit; LMCA=left main coronary artery; LV=left
ventricle; MI=myocardial infarction; SCr=Serum creatinine </p></fn></table-wrap-foot></table-wrap><sec><title>Mortality from all Causes in the 30-day Follow-up Period</title><p>There were 21 (9.5%) deaths in 30 days. The optimum cutoff value selected by ROC
curve was 150 pg/mL, the area under the curve was equal to 0.82 (CI 95% 0.72 to
0.91), with a sensitivity of 81% and a specificity of 46%, positive and negative
predictive values, respectively, equal to 24% and 95% for all-cause mortality in
30 days after CABG (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>ROC curve showing point of maximum sensitivity and specificity
correlating BNP measured in the preoperative and all-cause mortality
during the 30-day postoperative period.</p></caption><graphic xlink:href="rbccv-32-06-0462-g02"/></fig>
</p><p>When stratified according to the optimal cutoff value of the preoperative serum
BNP concentration equal to 150 pg/dl, the group of patients with BNP greater
than or equal to 150 mg/dl was older (58 years <italic>versus</italic> 62 years,
<italic>P</italic>=0.010), higher body mass index (28 kg/m<sup>2</sup>
<italic>versus</italic> 26 kg/m<sup>2</sup>, <italic>P</italic>=0.010), in the
presence of acute coronary syndrome (20% <italic>versus</italic> 47%,
<italic>P</italic>&#x0003c;0.0010, urgency/emergency surgery 21%
<italic>versus</italic> 54%, <italic>P</italic>&#x0003c;0.001), higher rate of
the left ventricular dysfunction (9.9% <italic>versus</italic> 29%,
<italic>P</italic>&#x0003c;0.001), intra-aortic balloon use (8.1%
<italic>versus</italic> 18%, <italic>P</italic>=0.027) and higher EuroSCORE
additive (2 <italic>versus</italic> 3, <italic>P</italic>&#x0003c;0.001) (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>
<xref ref-type="table" rid="t2">Table 2</xref> shows the variables univariate
associated with mortality in 30 days, as well as the independent predictors
determined by the multivariate Cox regression analysis. In order of prognostic
importance, the time of extracorporeal circulation (<italic>P</italic>=0.027,
HR=1.02, 95% CI 1.00- 1.03), age (<italic>P</italic>&#x0003c;0.001, HR=1.1, 95% CI
1.04-1.16), preoperative serum creatinine (<italic>P</italic>&#x0003c;0.001, HR =
1.95, 95% CI 1.42-2.68), BNP greater than or equal to 150 pg/ml
(<italic>P</italic>=0.030, HR=3.99, 95% CI 1.14-13.98) were independent
predictors of all-cause death in the 30-day postoperative followup period.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Univariate and multivariate analysis by the Cox Regression model for
mortality in the 30-day postoperative period.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">All patients</th><th align="center" colspan="3" rowspan="1">Univariate</th><th align="center" colspan="3" rowspan="1">Multivariate</th></tr><tr><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">1.10</td><td align="center" rowspan="1" colspan="1">1.05 &#x02013; 1.16</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.10</td><td align="center" rowspan="1" colspan="1">1.04 &#x02013; 1.16</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (male)</td><td align="center" rowspan="1" colspan="1">1.04</td><td align="center" rowspan="1" colspan="1">0.42 &#x02013; 2.58</td><td align="center" rowspan="1" colspan="1">0.930</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Urgency/emergency surgery</td><td align="center" rowspan="1" colspan="1">5.94</td><td align="center" rowspan="1" colspan="1">2.17 &#x02013; 16.21</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline SCr (mg/dL)</td><td align="center" rowspan="1" colspan="1">2.44</td><td align="center" rowspan="1" colspan="1">1.80 &#x02013; 3.30</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">1.42 &#x02013; 2.68</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LV Dysfunction</td><td align="center" rowspan="1" colspan="1">2.77</td><td align="center" rowspan="1" colspan="1">1.15 &#x02013; 6.70</td><td align="center" rowspan="1" colspan="1">0.023</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time (min)</td><td align="center" rowspan="1" colspan="1">1.03</td><td align="center" rowspan="1" colspan="1">1.01 &#x02013; 1.04</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.02</td><td align="center" rowspan="1" colspan="1">1.00 &#x02013; 1.03</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP &#x02265; 150 pg/mL</td><td align="center" rowspan="1" colspan="1">6.55</td><td align="center" rowspan="1" colspan="1">1.93 &#x02013; 22.23</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">3.99</td><td align="center" rowspan="1" colspan="1">1.14 &#x02013; 13.98</td><td align="center" rowspan="1" colspan="1">0.030</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>BNP=B-type natriuretic peptide; LV=left ventricle; SCr=Serum
creatinine</p></fn></table-wrap-foot></table-wrap><p>The survival probability of patients undergoing OPCABG was 90.5% in the 30-day
postoperative follow-up period. Survival for patients with BNP &#x02265; 150
pg/ml in 30 days was 83.6% and for those with BNP &#x0003c;150 pg/ml was 97.3%
(<italic>P</italic>&#x0003c;0.001, <xref ref-type="fig" rid="f3">Figure
3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Kaplan Meier survival curves for patients undergoing CABG stratified
for serum preoperative BNP.</p></caption><graphic xlink:href="rbccv-32-06-0462-g03"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This prospective study with a significant cohort revealed independent predictors of
all-cause mortality in patients undergoing OPCABG. In ascending order of prognostic
importance, the factors were time of extracorporeal circulation, age, preoperative
serum creatinine, and preoperative serum BNP concentration &#x02265; 150 pg/ml.</p><p>Predictors of short-term mortality in CABG have been well established in the last
decades. Consequently, risk stratification systems were created with the objective
of predicting shortterm mortality after CABG and the most employed in the USA and
Europe are, respectively, the STS risk score and EuroSCORE II. Widely validated in
thousands of patients in a multicenter database, these systems have contributed to a
progressive decline in mortality in the short-term and are recommended as a gold
standard model for risk stratification in CABG<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r11" ref-type="bibr">11</xref>-<xref rid="r15" ref-type="bibr">15</xref>]</sup>. It is necessary to identify new variables
capable of improving and better predict short-term results in myocardial
revascularization surgery. In this context, the role of preoperative serum BNP
concentration as a risk stratification instrument in cardiac surgery has been
investigated and further studies are needed to determine the actual clinical
usefulness of BNP in relation to already validated risk stratification
systems<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><p>In our study, preoperative serum BNP concentration greater than 150 pg/mL was an
independent predictor of mortality with the hazard ratio (HR) function equal to 3.96
(<italic>P</italic>=0.006, 95% CI 1.50 - 10.50) and a significant reduction in
the probability of survival in 30 days. In patients undergoing OPCABG, the use of
preoperative serum BNP concentration had already been evaluated as a predictor of
adverse clinical events. Bernstein et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> previously demonstrated that the preoperative serum
concentration of high BNP was associated with a higher incidence of postoperative
atrial fibrillation and longer hospital stay. In a study by Cuthbertson et
al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, a higher
preoperative concentration of BNP was a predictor of greater need for hemodynamic
support and longer time in the intensive care unit. However, in a study by Chen et
al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, the preoperative
serum BNP concentration has not presented a significant association with the length
of hospital stay and rehospitalization after elective CABG.</p><p>Regarding all-cause surgical mortality, our group found significant preliminary
results in a group of patients underwent cardiac valve or CABG, demonstrating a
significant association between higher preoperative serum BNP concentration and
short-term mortality<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>. According to these findings, a
systematic review by Litton &#x00026; Ho<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> showed a correlation between the preoperative serum BNP
concentration and mortality, however due to the slightly relevant accuracy, the
authors recommended in their study the clinical use of Judiciously.</p><p>Few studies specifically evaluated the preoperative BNP concentration in relation to
mortality after OPCABG. In a study by Fox et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, the peak perioperative serum BNP concentration
(preoperative up to the fifth postoperative day) was independently correlated with
the combined outcome of hospitalization or death from heart failure in 5 years of
follow-up. This study warned the need for clinical studies to evaluate whether a
medical therapy focused on reducing the perioperative concentration of BNP would be
able to reduce events after OPCABG.</p><p>At the present time, our study is original when it was designed methodologically with
the specific purpose of evaluating the preoperative serum concentration of BNP and
the short-term mortality after OPCABG, adding information to the scarce literature
on the subject. An important prognostic function of this hormone in myocardial
revascularization surgeries was shown. From the pathophysiological point of view, it
is implicit that higher levels of BNP correlate with greater ventricular parietal
tension, myocardial ischemia and its secretion and mechanism of action have a
cardioprotective effect in the attempt to promote systemic and coronary arterial
vasodilation, as well as venodilation with reduction of pre and post loading and
improvement of cardiac index<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>.</p><p>The relevance of the topic is evident, since the natriuretic system is currently the
focus of great therapeutic perspective in cardiovascular medicine. Although
metanalysis still shows uncertainties regarding the use of BNP to guide treatment in
patients with HF, the emergence of drugs (LCZ 696) acting directly on the enzyme
system (neprilysin inhibitors) responsible for the degradation of BNP demonstrated a
significant reduction in cardiovascular mortality in patients with heart failure and
its clinical use is already authorized by regulatory agencies in some
countries<sup>[<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>.</p><p>Our group believes that the high preoperative serum BNP concentration characterizes a
group of patients with a higher risk of death in myocardial revascularization
surgeries and that new therapies guided by the level of BNP and drugs acting on its
metabolic pathway may come to collaborate for a possible additional reduction of
mortality after this surgical procedure.</p><p>A limitation of our study consists of a relatively small number of patients followed
up, however, it can still be considered one of the largest studies among those
related on the subject in the literature.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The preoperative serum concentration of BNP is a strong independent predictor of
all-cause mortality during the 30-day postoperative period in patients undergoing
OPCABG.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">JAMJ</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content; agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published;</td></tr><tr><td align="left" rowspan="1" colspan="1">MNM</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published;</td></tr><tr><td align="left" rowspan="1" colspan="1">MPF</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published;</td></tr><tr><td align="left" rowspan="1" colspan="1">MJFS</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published;</td></tr><tr><td align="left" rowspan="1" colspan="1">IHG</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published;</td></tr><tr><td align="left" rowspan="1" colspan="1">CCS</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published;</td></tr><tr><td align="left" rowspan="1" colspan="1">MFG</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published.</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="supported-by"><p>This study was carried out at Faculdade de Medicina de S&#x000e3;o Jos&#x000e9; do
Rio Preto (FAMERP), S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>Kieser</surname><given-names>TM</given-names></name><name><surname>Falk</surname><given-names>V</given-names></name><name><surname>Huysmans</surname><given-names>HA</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name></person-group><article-title>Coronary artery bypass grafting: part 1-the evolution over the
first 50 years</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>37</issue><fpage>2862</fpage><lpage>2872</lpage><pub-id pub-id-type="pmid">24086085</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkes</surname><given-names>AL</given-names></name><name><surname>Nowak</surname><given-names>M</given-names></name><name><surname>Bidstrup</surname><given-names>B</given-names></name><name><surname>Speare</surname><given-names>R</given-names></name></person-group><article-title>Outcomes of coronary artery bypass graft surgery</article-title><source>Vasc Health Risk Manag</source><year>2006</year><volume>2</volume><issue>4</issue><fpage>477</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">17323602</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>TB Jr</given-names></name></person-group><article-title>Mortality in coronary artery bypass grafting: what's
next?</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>20</issue><fpage>2409</fpage><lpage>2411</lpage><pub-id pub-id-type="pmid">22547672</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>TB Jr</given-names></name><name><surname>Hammill</surname><given-names>BD</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>DeLong</surname><given-names>ER</given-names></name><name><surname>Grover</surname><given-names>FL</given-names></name></person-group><article-title>STS National Database Committee. A decade of change: risk
profiles and outcomes for isolated coronary artery bypass grafting
procedures, 1990-1999: a report from the STS National Database Committee and
the Duke Clinical Research Institute. Society of Thoracic
Surgeons</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>73</volume><issue>2</issue><fpage>480</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">11845863</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>Oliveira</surname><given-names>MA</given-names></name><name><surname>Brandi</surname><given-names>AC</given-names></name><name><surname>Botelho</surname><given-names>PH</given-names></name><name><surname>Brandi</surname><given-names>JC</given-names></name><name><surname>Santos</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Risk factors for mortality of patients undergoing coronary artery
bypass graft surgery</article-title><source>Rev Bras Cir Cardiovasc</source><year>2014</year><volume>29</volume><issue>4</issue><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">25714203</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gimenes</surname><given-names>C</given-names></name><name><surname>Barrile</surname><given-names>SR</given-names></name><name><surname>Martinelli</surname><given-names>B</given-names></name><name><surname>Ronchi</surname><given-names>CF</given-names></name><name><surname>Arca</surname><given-names>EA</given-names></name><name><surname>Gimenes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Association of pre and intraoperative variables with
postoperative complications in coronary artery bypass graft
surgery</article-title><source>Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><issue>4</issue><fpage>518</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">24598958</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Camacho</surname><given-names>FT</given-names></name><name><surname>Wechsler</surname><given-names>AS</given-names></name><name><surname>Lahey</surname><given-names>S</given-names></name><name><surname>Culliford</surname><given-names>AT</given-names></name><name><surname>Jordan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Risk score for predicting long-term mortality after coronary
artery bypass graft surgery</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>20</issue><fpage>2423</fpage><lpage>2430</lpage><pub-id pub-id-type="pmid">22547673</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahian</surname><given-names>DM</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Grover</surname><given-names>FL</given-names></name><name><surname>Grunkemeier</surname><given-names>GL</given-names></name><name><surname>Naftel</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Cardiac surgery risk models: a position article</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>5</issue><fpage>1868</fpage><lpage>1877</lpage><pub-id pub-id-type="pmid">15511504</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasue</surname><given-names>H</given-names></name><name><surname>Yoshimura</surname><given-names>M</given-names></name><name><surname>Sumida</surname><given-names>H</given-names></name><name><surname>Kikuta</surname><given-names>K</given-names></name><name><surname>Kugiyama</surname><given-names>K</given-names></name><name><surname>Jougasaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Localization and mechanism of secretion of B-type natriuretic
peptide in comparison with those of A-type natriuretic peptide in normal
subjects and patients with heart failure</article-title><source>Circulation</source><year>1994</year><volume>90</volume><issue>1</issue><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">8025996</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Alfonso</surname><given-names>F</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Cremer</surname><given-names>J</given-names></name><name><surname>Falk</surname><given-names>V</given-names></name><etal/></person-group><article-title>2014 ESC/EACTS Guidelines on myocardial revascularization: the
Task Force on Myocardial Revascularization of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Developed with the special contribution of the European Association
of Percutaneous Cardiovascular Interventions (EAPCI)</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>37</issue><fpage>2541</fpage><lpage>2619</lpage><pub-id pub-id-type="pmid">25173339</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffolo</surname><given-names>E</given-names></name></person-group><article-title>Risk scores: coronary artery bypass grafting with and without
cardiopulmonary bypass</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>4</issue><fpage>III</fpage><lpage>IIV</lpage><pub-id pub-id-type="pmid">23515743</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>EL</given-names></name><name><surname>Westphal</surname><given-names>GA</given-names></name><name><surname>Mastroeni</surname><given-names>MF</given-names></name></person-group><article-title>Demographic and clinical characteristics of patients undergoing
coronary artery bypass graft surgery and their relation to
mortality</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>1</issue><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">22729301</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mej&#x000ed;a</surname><given-names>OA</given-names></name><name><surname>Lisboa</surname><given-names>LA</given-names></name><name><surname>Tiveron</surname><given-names>MG</given-names></name><name><surname>Santiago</surname><given-names>JA</given-names></name><name><surname>Tineli</surname><given-names>RA</given-names></name><name><surname>Dallan</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Coronary artery bypass grafting in acute myocardial infarction:
analysis of predictors of in-hospital mortality</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>1</issue><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">22729303</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Salamon</surname><given-names>R.</given-names></name></person-group><article-title>European system for cardiac operative risk evaluation
(EuroSCORE)</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>16</volume><issue>1</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10456395</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Algotsson</surname><given-names>L</given-names></name><name><surname>Hoglund</surname><given-names>P</given-names></name><name><surname>Luhrs</surname><given-names>C</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name></person-group><article-title>Comparison of 19 pre-operative risk stratification models on
open-heart surgery</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>7</issue><fpage>867</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">16421172</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murad Junior</surname><given-names>JA</given-names></name><name><surname>Nakazone</surname><given-names>MA</given-names></name><name><surname>Machado</surname><given-names>MN</given-names></name><name><surname>Godoy</surname><given-names>MF</given-names></name></person-group><article-title>Predictors of mortality in cardiac surgery: brain natriuretic
peptide type B</article-title><source>Rev Bras Cir Cardiovasc</source><year>2015</year><volume>30</volume><issue>2</issue><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">26107449</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murad Junior</surname><given-names>JA</given-names></name><name><surname>Machado</surname><given-names>MN</given-names></name><name><surname>Martins</surname><given-names>THP</given-names></name><name><surname>Maia</surname><given-names>LN</given-names></name><name><surname>Nakazone</surname><given-names>MA</given-names></name></person-group><article-title>Brain natriuretic peptide as a predictor of clinical adverse
events in cardiac surgery: a single- center prospective
study</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><issue>13</issue><elocation-id>E1818</elocation-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>E</given-names></name><name><surname>Block</surname><given-names>R</given-names></name><name><surname>Veazie</surname><given-names>P</given-names></name><name><surname>Tompkins</surname><given-names>C</given-names></name><name><surname>Bashour</surname><given-names>CA</given-names></name><name><surname>Turan</surname><given-names>A</given-names></name></person-group><article-title>Preoperative brain natriuretic peptide and atrial arrhythmias
after coronary artery bypass graft surgery</article-title><source>J Cardiothorac Vasc Anesth</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">25847409</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuthbertson</surname><given-names>BH</given-names></name><name><surname>McKeown</surname><given-names>A</given-names></name><name><surname>Croal</surname><given-names>BL</given-names></name><name><surname>Mutch</surname><given-names>WJ</given-names></name><name><surname>Hillis</surname><given-names>GS</given-names></name></person-group><article-title>Utility of B-type natriuretic peptide in predicting the level of
peri and postoperative cardiovascular support required after coronary artery
bypass grafting</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><issue>2</issue><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">15699850</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Shih</surname><given-names>JJM</given-names></name><name><surname>Shih</surname><given-names>JYM</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Plasma B-type natriuretic peptide in predicting outcomes of
elective coronary artery bypass surgery</article-title><source>Kaohsiung J Med Sciences</source><year>2013</year><volume>29</volume><fpage>254</fpage><lpage>258</lpage></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litton</surname><given-names>E</given-names></name><name><surname>Ho</surname><given-names>KM</given-names></name></person-group><article-title>The use of pre-operative brain natriuretic peptides as a
predictor of adverse outcomes after cardiac surgery: a systematic review and
meta-analysis</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>41</volume><issue>3</issue><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">22345176</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>AA</given-names></name><name><surname>Shernan</surname><given-names>SK</given-names></name><name><surname>Collard</surname><given-names>CD</given-names></name><name><surname>Liu</surname><given-names>KY</given-names></name><name><surname>Aranki</surname><given-names>SF</given-names></name><name><surname>DeSantis</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Preoperative B-type natriuretic peptide is as independent
predictor of ventricular dysfunction and mortality after primary coronary
artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2008</year><volume>136</volume><issue>2</issue><fpage>452</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">18692657</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>JA</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Drazner</surname><given-names>MH</given-names></name></person-group><article-title>B-type natriuretic peptide in cardiovascular
disease</article-title><source>Lancet</source><year>2003</year><volume>362</volume><issue>9380</issue><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">12892964</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balion</surname><given-names>C1</given-names></name><name><surname>Mckelvie</surname><given-names>R</given-names></name><name><surname>Don-Wauchope</surname><given-names>AC</given-names></name><name><surname>Santaguida</surname><given-names>PL</given-names></name><name><surname>Oremus</surname><given-names>M</given-names></name><name><surname>Keshavarz</surname><given-names>H</given-names></name><etal/></person-group><article-title>B-type natriuretic peptide-guided therapy: a systematic
review</article-title><source>Heart Fail Rev</source><year>2014</year><volume>19</volume><issue>4</issue><fpage>553</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">25074674</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Packer</surname><given-names>M</given-names></name><name><surname>Desai</surname><given-names>AS</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Lefkowitz</surname><given-names>MP</given-names></name><name><surname>Rizkala</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Angiotensin-neprilysin inhibition versus enalapril in heart
failure</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>11</issue><fpage>993</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">25176015</pub-id></element-citation></ref></ref-list></back></article>